Subcortical white matter abnormalities related to drug resistance in Wilson disease

**Abstract**—Wilson disease (WD) produces typical lesions in the brain, which can aid in diagnosis and therapy. The authors present a drug-resistant WD case with atypical cerebral lesions with marked involvement of white matter as visualized on MRI scans. The diagnosis was confirmed by identification of mutations in the *ATP7B* gene. The case demonstrates an uncommon pathology-related cerebral copper accumulation and emphasizes the importance of genetic screening in the diagnosis of WD.

**NEUROLOGY 2006;67:878–880**

D. Aikath, MBBS*; A. Gupta, MSc*; I. Chattopadhyay, PhD; M.A. Hashmi, MD (Radio); P.K. Gangopadhyay, DM (Neuro); S.K. Das, DM (Neuro); and K. Ray, PhD

Wilson disease (WD) is an autosomal recessive metabolic disorder of copper accumulation, caused by defects in the gene for *ATP7B*, a P-type ATPase, responsible for the transport of copper to the vesicles for excretion. WD manifests with hepatic and neurologic findings, with or without accompanying psychiatric features. The common neurologic features are rigidity, dystonia of limbs and trunk, dysarthria, tremor, and drooling. The diagnosis of purely neurologic forms of WD is difficult, with a mean delay of 12.8 years. A T2-weighted MRI scan aids the diagnosis of cases where the accumulation of copper in the subcortical gray matter and other areas produces typical lesions as visualized by T2-weighted and fluid-attenuated inversion recovery images.

Here, we describe a patient with a neurologic WD, who failed to respond to treatment for 3 years. MRI scans of the brain show atypical changes, though the patient was not diagnosed with any other neurologic disease. The case represents a neural pathogenesis that causes higher involvement of white matter and gross and disproportionate cerebral atrophy.

**Case summary.** The 11-year-old boy was born to nonconsanguinous parents and had normal developmental milestones. He presented with an 8-month history of difficulty of movement starting from the right toes, and a 2-month history of slurring of speech. He had behavioral abnormalities in the form of anger outbursts, refusal to talk for prolonged periods (up to 2 weeks), and uncontrolled laughter. There were two episodes of loss of consciousness lasting 5 minutes each about 2 years before presentation, without any complications.

The patient was uncooperative, severely dysarthric, and unable to follow verbal commands. He had K-F rings in both eyes. All four limbs were wasted, with dystonic posture, and with contracture at the ankles. Tone of the flexors was increased in the upper limbs, and extensors were increased in the lower limbs. Palmaromental reflex was positive, and deep tendon reflexes of lower limbs were brisk, plantar response being bilaterally extensor. Episodes of hypotension were never recorded.

In spite of treatment with d-penicillamine and other symptom-reducing drugs (e.g., antidystonic drugs) for 3 years, the patient became completely bedridden and worsened clinically. He was not responding to painful stimuli and was severely distressed and dystonic. All four limbs were flexed and rigid, with contracture of the hamstrings and the calf muscles. However, plantar response had become bilaterally flexor. He had incontinence of bowels and bladder. Three years later, the patient died of severe respiratory infections.

The serum ceruloplasmin level of the patient was 8.5 mg/dL (normally >20 mg/dL) and 24-hour urinary copper excretion level was 92 µg (normally <100 µg). The serum copper level was 19 µg/dL (normally 75 to 145 µg/dL). The serum albumin/globulin ratio was 1.05 (normally about 1.7). Liver biochemistry and ultrasound examination and blood and urine biochemistry and pathology were normal. Normal leukocyte arylsulfatase A and serum lactate levels rule out the possibility of metachromatic leukodystrophy and Leigh disease.

A typical MRI seen in WD (figure, C) shows bilateral symmetry of gray matter affecting mainly putamen, caudate, thalamus, and globus pallidus and less commonly asymmetrical white matter lesions in centrum semiovale and subcortical frontotemporal and occipital regions. Early MRI in our patient also demonstrated typical T2-weighted hyperintensities in the putamen and thalamic regions (figure, A). Subsequently, after 3 years of therapy (figure, B), there was extensive subcortical white matter hyperintensities affecting frontal, temporal, and parietal regions and marked hypointensity in the putaminal region in the same sequence. There was also hypointensity of T2-weighted hyperintensities affecting the spinal cord, cervical roots, and cauda equine. The hypointensity of T2-weighted images became more evident and extended to the whole lentiform nuclei, which might be due to deposition of iron in exchange of copper, as also described by others.

MRS using long echo time (144 milliseconds) showed rise in the choline/creatinine ratio and notably presence of lactate waves in comparison with a typical WD patient (figure, D). Normally at this age, the myelination process is almost complete and high choline peaks are rare. However, N-acetylaspartate levels were almost normal, showing neuronal integrity. Scans taken at the time of presentation showed mild involvement of bilateral basal ganglia and putaminal region. The peripheral white matter was less involved at that time, and there was no ventricular dilatation. Over the last 3 years, there had been a marked increase in white matter involvement and atrophy of the basal ganglia had taken place.

This disproportionately high involvement of white matter in...
Discussion. In our patient, the clinical and biochemical findings at presentation suggested neurologic WD. However, the patient did not respond to the chelation therapy, which is usually of benefit to neurologic patients, improving clinical features and reversing MRI findings. MRI was undertaken to assess the course of the disease as well as to validate the diagnosis. However, the scans showed a disproportionately high involvement of white matter and gross atrophy of cortical gray matter in relation to basal ganglia, which is unusual for WD. In addition to extrapyramidal involvement, which is common in WD due to subcortical gray matter damage, we found brisk deep tendon reflexes and extensor plantar response showing pyramidal lesions. This observation, though unusual, was consistent with the degeneration of white matter (internal capsule) and cortical gray matter seen on MRI. Identification of two mutations, both reported in other WD patients, confirmed the case being investigated as WD.

The exaggerated involvement of white matter might be due to copper transported from the cell body or due to the damage to the glial tissues (oligodendroglia and Schwann cells). The simultaneous involvement of the cortical neurons and the internal capsule (comprising their axons) favors the former possibility. The involvement of the cortical neuron may be due to the nonfunctioning of the copper-dependent enzymes in those regions. It has been reported that ATP7B plays an important role in development of cerebellum. Moreover, this kind of damage appears to be less amenable to reversal through chelation therapy.

Acknowledgment
The authors thank the patients for participating in the study and Mr. Pradip Chandra Nag and Dr. Sanjay Nag for processing of MR images.

References

Figure. MRI and MRS showing atypical and typical findings in Wilson disease (WD). (A) MRI scans of the patient at presentation, which show mild bilateral putaminal and thalamic hyperintensities. Not much change is seen in the frontal lobes, though signal changes are already evident in the parietal lobes. There is no ventricular dilatation. (B) Scans of the same patient taken after 3 years of therapy, showing atrophy of the basal ganglia and cortex, with ex vacuo dilatation of the ventricular system. Involvement of the frontoparietotemporal white and gray matter is conspicuous and atypical. (C) Typical findings in a neurologic case of WD who presented at 11 years. The scans, taken after three years of therapy, show bilaterally symmetric hyperintensities in the putaminal and thalamic regions. No involvement of the frontal and parietal lobes is seen.
Brain shrinkage due to acute hypernatremia
Takeshi Machino, MD; and Toshihiro Yoshizawa, MD, PhD, Ibaraki and Tsukuba, Japan

A 73-year-old man presented with vomiting, tremor, and consciousness disturbance 12 hours after ingesting soy sauce in an attempt to commit suicide. His serum sodium was 188 mEq/L and chloride 142 mEq/L. Serum osmolarity was a high 314 mOsm/kg H₂O. T1- and T2-weighted brain MRI showed symmetric brain shrinkage and subdural fluid collection around the cerebral cortex (figure, A and B). Under a diagnosis of acute hypernatremia due to excessive NaCl intake, we corrected his hypernatremia within the next 48 hours, and his condition improved rapidly. No renal dysfunction was observed. To evaluate brain volume restoration, we repeated MRI 3 weeks after onset. Although some subdural fluid collection appeared to remain, brain volume restored (figure, C and D). Acute hypernatremia shrinks the brain by dehydrating it.1 Our case shows that reversible brain shrinkage and compensatory widening of the subdural space are hallmarks of brain dehydration.

Disclosure: The authors report no conflicts of interest.

Address correspondence and reprint requests to Dr. T. Yoshizawa, Department of Neurology, Institute of Clinical Medicine, Graduate School of Comprehensive Medical Sciences, University of Tsukuba, Tsukuba 305-8575, Japan; e-mail: toshi-ya@md.tsukuba.ac.jp

Copyright © 2006 by AAN Enterprises, Inc.

Figure. (A) T1- and (B) T2-weighted MRI shortly after admission show brain shrinkage and compensatory widening of the subdural space. (B) Subdural fluid collection is clear in this T2-weighted image. (C, D) Restoration of brain volume is shown in MRI follow-up 3 weeks after onset.

Brain shrinkage due to acute hypernatremia
Takeshi Machino and Toshihiro Yoshizawa

*Neurology* 2006;67;880
DOI 10.1212/01.wnl.0000221726.41727.06

This information is current as of September 11, 2006

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://www.neurology.org/content/67/5/880.full.html">http://www.neurology.org/content/67/5/880.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>References</td>
<td>This article cites 1 articles, 0 of which you can access for free at: <a href="http://www.neurology.org/content/67/5/880.full.html##ref-list-1">http://www.neurology.org/content/67/5/880.full.html##ref-list-1</a></td>
</tr>
<tr>
<td>Citations</td>
<td>This article has been cited by 1 HighWire-hosted articles: <a href="http://www.neurology.org/content/67/5/880.full.html##otherarticles">http://www.neurology.org/content/67/5/880.full.html##otherarticles</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s):</td>
</tr>
<tr>
<td></td>
<td><strong>Electrolyte</strong> <a href="http://www.neurology.org/cgi/collection/electrolyte">http://www.neurology.org/cgi/collection/electrolyte</a></td>
</tr>
<tr>
<td></td>
<td><strong>MRI</strong> <a href="http://www.neurology.org/cgi/collection/mri">http://www.neurology.org/cgi/collection/mri</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: <a href="http://www.neurology.org/misc/about.xhtml#permissions">http://www.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://www.neurology.org/misc/addir.xhtml#reprintsus">http://www.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>